- Home
- YCBD vs GNPX Comparison
YCBD vs GNPX Comparison
Compare YCBD & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YCBD
- GNPX
- Stock Information
- Founded
- YCBD 2015
- GNPX 2009
- Country
- YCBD United States
- GNPX United States
- Employees
- YCBD N/A
- GNPX N/A
- Industry
- YCBD Biotechnology: Pharmaceutical Preparations
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- YCBD Health Care
- GNPX Health Care
- Exchange
- YCBD Nasdaq
- GNPX Nasdaq
- Market Cap
- YCBD 7.8M
- GNPX 6.6M
- IPO Year
- YCBD N/A
- GNPX 2018
- Fundamental
- Price
- YCBD $0.95
- GNPX $0.27
- Analyst Decision
- YCBD Strong Buy
- GNPX
- Analyst Count
- YCBD 1
- GNPX 0
- Target Price
- YCBD $3.00
- GNPX N/A
- AVG Volume (30 Days)
- YCBD 67.8K
- GNPX 1.2M
- Earning Date
- YCBD 08-13-2025
- GNPX 08-08-2025
- Dividend Yield
- YCBD N/A
- GNPX N/A
- EPS Growth
- YCBD N/A
- GNPX N/A
- EPS
- YCBD N/A
- GNPX N/A
- Revenue
- YCBD $19,593,146.00
- GNPX N/A
- Revenue This Year
- YCBD $13.00
- GNPX N/A
- Revenue Next Year
- YCBD $10.00
- GNPX N/A
- P/E Ratio
- YCBD N/A
- GNPX N/A
- Revenue Growth
- YCBD N/A
- GNPX N/A
- 52 Week Low
- YCBD $0.76
- GNPX $0.20
- 52 Week High
- YCBD $6.54
- GNPX $3.97
- Technical
- Relative Strength Index (RSI)
- YCBD 51.65
- GNPX 49.37
- Support Level
- YCBD $0.90
- GNPX $0.25
- Resistance Level
- YCBD $0.99
- GNPX $0.29
- Average True Range (ATR)
- YCBD 0.06
- GNPX 0.02
- MACD
- YCBD 0.01
- GNPX -0.00
- Stochastic Oscillator
- YCBD 58.90
- GNPX 34.37
About YCBD cbdMD Inc.
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.